Suction-assisted lipectomy for lipodystrophy

AIDS Research and Human Retroviruses

Volumn 20, Issue 8, 2004, Pages 813-815

  Connolly, Nancy ^a,b   Manders, Ernest ^a   Riddler, Sharon ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPECTOMY; LIPOSUCTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; HIV PROTEASE INHIBITORS; HUMANS; LIPECTOMY; LIPODYSTROPHY; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME;

EID: 4344630710     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041725208     Document Type: Article

References (13)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Saves M, Raffi F, Capeau J, et al.: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-1405.
3. Currier, J, Carpenter C, Daar, E, et al.: Identifying and managing morphologic complications of HIV and HAART. AIDS Reader March 2002.
4. Duran S, Saves M, Spire B, et al.: The APROCOC Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15(18): 2441-2444.
5. Ponce-de-Leon S, Iglesias M, Ceballos J, et al.: Liposuction for protease-inhibitor associated lipodystrophy. Lancet 1999;353(9160): 1244.
6. Wolfort FG, Cetrulo CL Jr, and Nevarre DR: Suction-assisted lipectorny for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg 1999;104(6):1814-1820.
7. Shevitz A, Wanke CA, Falutz J, et al.: Clinical perspectives on HIV-associated lipodystrophy syndrome: An update. AIDS 2001;15(15):1917-1930.
8. Catz SL, Kelly JA, Bogart LM, et al.: Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19(2):124-133.
9. Carr A, Hudson J, Chuah J, et al.: The PIILR Study Group. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001;15(14):1811-1822.
10. Dukers NH, Stolte IG, Albrecht N, et al.: The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS 2001;15(6):812-813.
11. Lichtenstein KA, Ward DJ, Moorman AC, et al., HIV Outpatient Study Investigators: Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15(11):1389-1398.
12. Heath KV, Hogg RS, Chan KJ, et al.: Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15(2):231-239.
13. Safrin S and Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13(18):2493-2505.